Applications of Viral Vectors in Lung Cancer Gene Therapy
Viral vectors are powerful tools for gene delivery in lung cancer research due to their high transduction efficiency and ability to mediate stable gene expression. Commonly used viral systems include adenoviruses, lentiviruses, and adeno-associated viruses (AAV), each offering distinct advantages for different experimental needs.
Adenoviral vectors provide high transgene expression levels and are often employed in transient gene expression studies and vaccine development. Their broad tropism allows infection of both dividing and non-dividing lung cancer cells, such as those found in adenocarcinoma and squamous cell carcinoma. However, immune responses to adenoviruses can limit their use in some therapeutic applications.
Lentiviral vectors integrate into the host genome, enabling stable, long-term expression of target genes or RNA interference constructs. This makes them ideal for studying gene function, creating lung cancer cell models with sustained gene knockdown or overexpression, and screening therapeutic targets. Lentiviruses can transduce a wide range of lung cancer cell types with relatively low immunogenicity.
AAV vectors offer a safer profile with minimal integration risk and low immunogenicity, but their smaller packaging capacity restricts the size of therapeutic genes. AAV-based gene delivery is increasingly explored for lung cancer applications, especially for gene editing and delivery of tumor suppressors.
Despite their utility, viral vectors require careful handling due to biosafety concerns and potential insertional mutagenesis. Advances in vector engineering, including self-inactivating constructs and tissue-specific promoters, enhance safety and specificity.
Viral vector-mediated gene delivery continues to expand the toolkit for lung cancer research, enabling functional studies, therapeutic gene transfer, and preclinical evaluation of gene therapies.
References: Altogen.com Altogenlabs.com